Trial reportAmerican heart journal2010
beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing.
Trial report in American heart journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction.Journal of the American College of Cardiology · 2015Trial
- Early administration of ivabradine in patients with acute anterior ST-elevation myocardial infarction: a prospective, randomized, open-label study on in-hospital and short-term major adverse cardiac events and left ventricular function.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- Cost-effectiveness of outpatient adherence to recommendations for monitoring of patients hospitalized for heart failure.ESC heart failure · 2024Article
- Long-Term Follow-Up After Acute Myocardial Infarction According to Beta-Blocker Dose.The American journal of medicine · 2023Article
- Evaluation of metoprolol standard dosing pathway in Chinese patients with acute coronary syndrome: a prospective multicenter single-arm interventional study.Journal of geriatric cardiology : JGC · 2023Article
- Sex-Related Differences in Outpatient Healthcare of Acute Coronary Syndrome: Evidence from an Italian Real-World Investigation.Journal of clinical medicine · 2023Article
- Carvedilol versus Metoprolol in Patients with Ventricular Tachyarrhythmias.Journal of cardiovascular development and disease · 2022Article
- Prognostic Value of Cardiac Troponin I in Patients with Ventricular Tachyarrhythmias.Journal of clinical medicine · 2022Article
- Adherence to recommendations for secondary prevention medications after myocardial infarction in Estonia: comparison of real-world data from 2004 to 2005 and 2017 to 2018.BMC cardiovascular disorders · 2021Article
- Adherence to beta-blockers and long-term risk of heart failure and mortality after a myocardial infarction.ESC heart failure · 2021Article
- Article
- Use of Bevacizumab and Ranibizumab for Wet Age-Related Macular Degeneration: Influence of CATT Results and Introduction of Aflibercept.American journal of ophthalmology · 2019Article
- Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD)-Current Considerations for Clinical Practice.Journal of clinical medicine · 2019Review
- Improving medication optimisation in left ventricular systolic dysfunction after acute myocardial infarction.BMJ open quality · 2019Article
- Evaluation of medication compliance for secondary prevention of acute coronary syndrome.Proceedings (Baylor University. Medical Center) · 2017Article
- Antianginal medications and long-term outcomes after elective catheterization in patients with coronary artery disease.Clinical cardiology · 2016Article
- Mortality reduction with use of oral beta-blockers in patients with acute coronary syndrome.Clinics (Sao Paulo, Brazil) · 2016Observational
- Beta-Blocker Therapy Early After Myocardial Infarction: A Comparison Between Medication at Hospital Discharge and Subsequent Pharmacy-Dispensed Medication.Drugs - real world outcomes · 2016Article
- Patient follow-up and monitoring medicines.Drug safety · 2011Article
- Differential effect of β-blockers for heart rate control in coronary artery disease.Clinical cardiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundQuality improvement programs have shown increased use of beta-blockers post-myocardial infarction (MI), but there are no data on whether appropriate doses are administered.
methodsIn a prospective registry that enrolled consecutive patients with MI, we evaluated beta-blocker dosing at discharge after MI and 3 weeks later and assessed clinical predictors for treatment with very low doses. We studied 1,971 patients (70.8% male) with a mean age of 63.9 +/- 13.7 years, of whom 48.2% had an ST-elevation MI.
resultsbeta-Blocker utilization rates following MI were 93.2% at discharge: 20.1% received <25% of target dose, 36.5% received 25% of target dose, 26.4% received 26% to 50% of target dose, and 17.0% received >50% of target dose. Between discharge and 3 weeks, 76.4% had no change in beta-blocker dose, with 11.9% and 11.6% having their dose reduced and increased, respectively. Absence of hypertension, acute percutaneous coronary intervention, older age, and no angiotensin-converting enzyme inhibitor therapy were consistent predictors of treatment with very low beta-blocker doses.
conclusionsUnderdosing of beta-blockers is highly prevalent among patients post-MI. This represents an important opportunity in quality improvement for the care of patients who have suffered an MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.